Loading organizations...
§ Private Profile · Boston, MA, USA
A biotechnology company developing transdermal drug delivery systems with microneedles for large-molecule drugs, replacing injections.
Based in Boston, Massachusetts, Anodyne Nanotech is a preclinical-stage biotechnology company that develops transdermal drug delivery systems to replace traditional subcutaneous injections. The enterprise utilizes its proprietary HeroPatch platform, which features solid-state porous microneedles, to administer clinically meaningful doses of large-molecule medicines such as biologics and GLP-1s directly through the skin. Operating as a business-to-business entity, the firm partners with pharmaceutical corporations to co-develop and license its non-invasive technology for chronic care treatments. The startup operates with up to 50 employees and has secured $8.45 million in total capital, including a $4.2 million seed financing round backed by Polaris Partners and the JDRF T1D Fund. Originally spun out of Tufts University and Brigham and Women's Hospital, the company was founded in 2019 by Jake Lombardo, Konstantinos Tzortzakis, Hojatollah Rezaei Nejad, and Nitin Joshi.
Anodyne Nanotech has raised $4.2M across 1 funding round.
Anodyne Nanotech has raised $4.2M in total across 1 funding round.
Anodyne Nanotech has raised $4.2M across 1 funding round. Most recently, it raised $4.2M Seed in May 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 3, 2021 | $4.2M Seed | — | BIG PI Ventures, Relativity Healthcare Partners, Velocity Partners | Announced |
Anodyne Nanotech has raised $4.2M in total across 1 funding round.
Anodyne Nanotech's investors include Big Pi Ventures, Relativity Healthcare Partners, Velocity Partners.